类风湿关节炎患者由参照阿达木单抗转换至SB5(阿达木单抗生物类似药)的52周III期随机研究结果
这项III期随机研究在542例中重度类风湿关节炎患者中评估SB5与参照阿达木单抗(ADA)的疗效、安全性和免疫原性至52周。第24周时ADA组患者再随机分为继续ADA(ADA/ADA组)或转换至SB5(ADA/SB5组),SB5组继续SB5至52周。结果显示转换后ACR20/50/70应答率得以维持,52周时ACR20应答率为73.4%至78.8%,各组影像学进展轻微且安全性及抗药抗体发生率相当。
要点
- 第24周由ADA转换至SB5后,ACR20/50/70应答率得以维持,各治疗组间整个研究期间应答率相当。
- 第52周时ACR20应答率范围为73.4%至78.8%。
- 各组影像学进展轻微且相当,转换后安全性和抗药抗体发生率各组相当。
核心结论
- SB5在类风湿关节炎患者中为期1年耐受良好,疗效、安全性和免疫原性与ADA相当。
- 由ADA转换至SB5未出现治疗 emergent 问题,如不良事件增加、免疫原性增加或疗效丧失。
研究设计与样本
- III期随机研究,患者初始按1:1随机接受SB5或ADA 40 mg皮下注射每两周一次。
- 第24周时ADA组患者再按1:1随机分为继续ADA(ADA/ADA组)或转换至SB5(ADA/SB5组)至第52周,SB5组继续SB5至52周。
- 全分析集共542例患者:SB5组269例,ADA总体组273例(第0周随机接受ADA者),ADA/SB5组125例,ADA/ADA组129例。
主要发现
- 第24周时达到ACR20、ACR50或ACR70应答的患者百分比在由ADA转换至SB5后得以维持,整个研究期间各治疗组应答率相当。
- 第52周时ACR20应答率范围为73.4%至78.8%。
- 各治疗组影像学进展轻微且相当。
- 转换后各治疗组安全性和抗药抗体发生率相当。
关键数值与推荐
- 第52周ACR20应答率范围为73.4%至78.8%。
- 全分析集542例:SB5组269例,ADA总体组273例,ADA/SB5组125例,ADA/ADA组129例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The 24-week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with moderate-to-severe rheumatoid arthritis (RA) have been reported previously. We undertook this transition study to evaluate patients who switched from ADA to SB5 or who continued to receive SB5 or ADA up to 52 weeks. METHODS: In this phase III study, patients were initially randomized 1:1 to receive SB5 or ADA (40 mg subcutaneously every other week). At 24 weeks, patients receiving ADA were rerandomized 1:1 to continue with ADA (ADA/ADA group) or to switch to SB5 (ADA/SB5 group) up to week 52; patients receiving SB5 continued with SB5 for 52 weeks (SB5 group). Efficacy, safety, and immunogenicity were evaluated up to 52 weeks. RESULTS: The full analysis set population consisted of 542 patients (269 in the SB5 group, 273 in the ADA overall group [patients who were randomized to receive ADA at week 0], 125 in the ADA/SB5 group, and 129 in the ADA/ADA group). The percentages of patients meeting the American College of Rheumatology 20%, 50%, or 70% improvement criteria (achieving an ACR20, ACR50, or ACR70 response) at week 24 were maintained after the transition from ADA to SB5, and these response rates were comparable across treatment groups throughout the study. ACR20 response rates ranged from 73.4% to 78.8% at week 52. Radiographic progression was minimal and comparable across treatment groups. The safety profile and the incidence of antidrug antibodies were comparable across treatment groups after transition. CONCLUSION: SB5 was well tolerated over 1 year in patients with RA, with efficacy, safety, and immunogenicity comparable to those of ADA. Switching from ADA to SB5 had no treatment-emergent issues such as increased adverse events, increased immunogenicity, or loss of efficacy.
引用
- Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. Arthritis Rheumatol. 2018. PMID: 29439289. doi:10.1002/art.40444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。